Department of Obstetrics and Gynecology, Zhangjiagang First People's Hospital, The Zhangjiagang Affiliated Hospital of Soochow University, Zhangjiagang, China.
Eur Rev Med Pharmacol Sci. 2017 Oct;21(20):4529-4535.
To investigate the expression level of long non-coding RNA promoter of CDKN1A antisense DNA damage activated RNA (lncRNA PANDAR) in cervical cancer and to analyze the effects of PANDAR on biological behaviors of cervical cancer and the clinical significance of PANDAR.
A total of 68 pairs of cervical cancer and paired cancer-adjacent tissue specimens were collected. The relative expression of PANDAR in tissues was detected by quantitative Real-time polymerase chain reaction (qRT-PCR) so as to analyze the relationship between PANDAR and clinicopathological factors of cervical cancer and evaluate its clinical significance. qRT-PCR was used to detect the relative expression of PANDAR in cervical cancer cells. Interference in PANDAR was conducted. Cell counting kit-8 (CCK-8) assay was used to detect the changes in cell proliferation capacity.
The results of qRT-PCR showed that the expression level of PANDAR was significantly up-regulated in cervical cancer tissues compared with that in cancer-adjacent tissues. Statistical analysis showed that PANDAR expression was correlated with International Federation of Gynecology and Obstetrics (FIGO) staging, tumor size and tumor invasion degree. Kaplan-Meier survival analysis showed that the survival time of patients with highly expressed PANDAR was shorter than that of patients with lowly expressed PANDAR. Cox multivariate regression analysis showed that PANDAR could be used as an independent prognostic factor for patients with cervical cancer. CCK-8 results showed that interference in PANDAR significantly inhibited tumor cell proliferation.
The expression level of PANDAR is up-regulated in cervical cancer tissues and cells, and PANDAR promotes tumor growth. PANDAR may be a biomarker for the early diagnosis of cervical cancer and a potential therapeutic target for reversing the malignant phenotype of tumors.
研究 CDKN1A 反义 DNA 损伤激活 RNA（lncRNA PANDAR）启动子在宫颈癌中的表达水平，并分析 PANDAR 对宫颈癌生物学行为的影响及其临床意义。
收集 68 对宫颈癌及配对癌旁组织标本，采用实时定量聚合酶链反应（qRT-PCR）检测组织中 PANDAR 的相对表达量，分析 PANDAR 与宫颈癌临床病理因素的关系，评估其临床意义。采用 qRT-PCR 检测宫颈癌细胞中 PANDAR 的相对表达量，干扰 PANDAR 后，采用细胞计数试剂盒-8（CCK-8）检测细胞增殖能力的变化。
qRT-PCR 结果显示，宫颈癌组织中 PANDAR 的表达水平明显高于癌旁组织。统计分析显示，PANDAR 的表达与国际妇产科联盟（FIGO）分期、肿瘤大小及肿瘤浸润程度有关。Kaplan-Meier 生存分析显示，PANDAR 高表达患者的生存时间短于 PANDAR 低表达患者。Cox 多因素回归分析显示，PANDAR 可作为宫颈癌患者的独立预后因素。CCK-8 结果显示，干扰 PANDAR 可显著抑制肿瘤细胞增殖。
PANDAR 在宫颈癌组织和细胞中呈高表达，促进肿瘤生长。PANDAR 可能是宫颈癌早期诊断的生物标志物，也是逆转肿瘤恶性表型的潜在治疗靶点。
